We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
+136.72%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
+$115M
Cap. Flow
+$11.9M
Cap. Flow %
3.81%
Top 10 Hldgs %
75.24%
Holding
35
New
15
Increased
2
Reduced
9
Closed
1

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$13M
2
PTCT icon
PTC Therapeutics
PTCT
+$10.4M
3
CYTK icon
Cytokinetics
CYTK
+$8.24M
4
ABVX
Abivax
ABVX
+$7.36M
5
INO icon
Inovio Pharmaceuticals
INO
+$4.4M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$16M
2
RVMD icon
Revolution Medicines
RVMD
+$15.4M
3
ITOS
iTeos Therapeutics
ITOS
+$8.23M
4
REPL icon
Replimune Group
REPL
+$7.42M
5
KYMR icon
Kymera Therapeutics
KYMR
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
1
Tango Therapeutics
TNGX
$4.21B
$82.1M 26.16%
9,771,485
– –
QURE icon
2
uniQure
QURE
$2.75B
$46.7M 14.88%
800,000
-99,500
-11% -$1.81M
RVMD icon
3
Revolution Medicines
RVMD
$38.5B
$18.7M 5.95%
400,000
-392,977
-50% -$15.4M
KYMR icon
4
Kymera Therapeutics
KYMR
$8.66B
$18.1M 5.76%
319,100
-112,910
-26% -$5.09M
KOD icon
5
Kodiak Sciences
KOD
$2.5B
$12.3M 3.91%
750,000
– –
PTCT icon
6
PTC Therapeutics
PTCT
$6.18B
$12.3M 3.91%
+200,000
New +$10.4M
AMLX icon
7
Amylyx Pharmaceuticals
AMLX
$2.19B
$12.2M 3.9%
900,000
-325,000
-27% -$3.06M
URGN icon
8
UroGen Pharma
URGN
$1.97B
$11.5M 3.66%
575,000
– –
MRUS
9
DELISTED
Merus
MRUS
$11.3M 3.6%
120,000
-245,000
-67% -$16M
CYTK icon
10
Cytokinetics
CYTK
$10.6B
$11M 3.5%
+200,000
New +$8.24M
ABVX
11
Abivax
ABVX
$10.4B
$10.2M 3.25%
+120,000
New +$7.36M
PTGX icon
12
Protagonist Therapeutics
PTGX
$8.55B
$7.31M 2.33%
110,000
+50,000
+83% +$2.84M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$7.11M 2.27%
125,000
– –
CBIO
14
Crescent Biopharma
CBIO
$546M
$5.39M 1.72%
453,686
– –
INO icon
15
Inovio Pharmaceuticals
INO
$85.6M
$5.38M 1.72%
+2,300,000
New +$4.4M
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.64B
$4.82M 1.54%
250,000
+225,000
+900% +$4.01M
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
$4.6M 1.47%
48,000
-7,000
-13% -$447K
CELC icon
18
Celcuity
CELC
$4.06B
$4.45M 1.42%
+90,000
New +$3.6M
REPL icon
19
Replimune Group
REPL
$454M
$4.4M 1.4%
1,050,000
-1,161,341
-53% -$7.42M
SLDB icon
20
Solid Biosciences
SLDB
$792M
$3.7M 1.18%
+600,000
New +$3.51M
DNLI icon
21
Denali Therapeutics
DNLI
$3.79B
$3.63M 1.16%
+250,000
New +$3.59M
PGEN icon
22
Precigen
PGEN
$1.94B
$2.8M 0.89%
+850,000
New +$2.4M
APGE icon
23
Apogee Therapeutics
APGE
$10.1B
$1.99M 0.63%
+50,000
New +$1.91M
DFTX
24
Definium Therapeutics
DFTX
$5.6B
$1.93M 0.61%
+163,500
New +$1.52M
MLTX icon
25
MoonLake Immunotherapeutics
MLTX
$1.56B
$1.79M 0.57%
+250,000
New +$13M
1
2

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
FTF
Freedom Together Foundation New York $762M AUM 15.13% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
PMWMG
Parr McKnight Wealth Management Group Minneapolis, Minnesota $763M AUM 13.49% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $763M AUM 30.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Boxer Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Boxer Capital Management held 35 positions worth $314M, up 58% from $199M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Boxer Capital Management deployed $11.9M of net new capital in Q3 2025, opening 15 new positions and adding to 2 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 250,000 shares worth $1.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $16M trimmed.

  • Boxer Capital Management's largest Q3 2025 buy was MoonLake Immunotherapeutics: 250,000 shares worth $1.79M.
  • Boxer Capital Management added most to Sarepta Therapeutics in Q3 2025, an estimated $4.01M increase.
  • Boxer Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $16M.
  • Boxer Capital Management fully exited iTeos Therapeutics in Q3 2025, selling an estimated $8.23M.
  • Boxer Capital Management's ten largest holdings make up 75% of its $314M portfolio in Q3 2025.
  • Boxer Capital Management opened 15 new positions and closed 1 in Q3 2025.
  • Boxer Capital Management's portfolio value rose 58% quarter-over-quarter to $314M.

Based on Boxer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.